Autres langues ADMA Biologics, Inc.

Actions

ADMA

US0008991046

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
6,58 ^USD	+0,46%		+0,61%	+45,58%

02/04	ADMA Biologics, Inc. annonce la promotion de Kaitlin Kestenberg au poste de chef de l'exploitation	CI
26/03	ADMA BIOLOGICS, INC. : HC Wainwright maintient sa recommandation à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	02/04
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing	20/03
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®	11/03
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	11/03
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference	05/03
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer	29/02
Adma Biologics: Q4 Earnings Snapshot	28/02
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q4 Revenue $73.9M, vs. Street Est of $73M	28/02
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025	28/02
ADMA Biologics Announces CFO Transition	28/02
ADMA Biologics Announces CFO Transition	28/02
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28/02
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28/02
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024	21/02
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024	21/02
ADMA Biologics Implements ADMAlytics AI Program to Bolster Production	21/02
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics	21/02
ADMA Biologics, Inc Successfully Implements Innovative AI Program, Named ADMAlytics	21/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ADMA Biologics, Inc.

Actions

ADMA

US0008991046

Autres langues

Filtres